Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NV-5138 in Treatment Resistant Depression
NCT05066672Phase 2Completed
- Sponsor
- Navitor Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mefluleucine in treatment-resistant depression (TRD), sponsored by Navitor Pharmaceuticals. Started Jan 2022; status: completed.
02
Drugs
mefluleucine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05066672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05066672.